Published in Cancer Weekly, May 2nd, 2000
The initial study, being conducted at the University of Iowa Cancer Center, is designed to evaluate the safety and immune activation of CpG DNA-based products in patients with relapsed or refractory non-Hodgkin's lymphoma. The company's two additional Phase I/II trials in cancer will begin later this quarter in Europe.
"The rapid initiation of these three clinical trials, our first studies of CpG 7909 in cancer patients, demonstrates our commitment...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.